Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients.
Fisher
B
B
Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA.
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards* / Q000706:statistics & numerical data; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001344:Autopsy; D002423:Cause of Death; D003625:Data Collection / Q000379:methods; D003627:Data Interpretation, Statistical; D003644:Death Certificates; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000401:mortality; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007258:Informed Consent; D008499:Medical Records / Q000592:standards; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D011643:Publishing; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018570:Risk Assessment; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen